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A set of 53 individuals from a population highly exposed to airbome hexachlorobenzene (HCB)
were selected to study the elimination kinetics ofthis chemical in humans. The volunteers provid-
ed blood, 24-hr urine, and feces samples for analysis of HCB and metabolites. The serum HCB
concentrations ranged from 2.4 to 1,485 ng/mL (mean * SD, 124 * 278), confirming that this
human population has the highest HCB blood levels ever reported. Al analyzed feces samples
contained unchanged HCB (range, 11-3,025 ng/g dry weight; mean * SD, 395 * 629). The
HCB concentration in feces strongly correlated with HCB in serum (r = 0.85; p < 0.001), sug-
gesting an equilibrium in feces/serum that is compatible with a main pulmonary entrance of the
chemical and low intestinal excretion of nonabsorbed foodborne HCB. The equilibrium is also
compatible with a nonbiliary passive tasfer of the chemical to the intestinal lumen. Two HCB
main metabolites, pentachlorophenol (PCP) and penhlorobenznethiol (PCBT), were detected
in 51% and 54% of feces samples, respectively. All urine samples contained PCP and PCBT, con-
firming the condusions of a previous study [Environ Health Perspect 105:78-83 (1997)]. The
comparison between feces and urie showed that whereas daily urinary elimination ofmetabolites
may account for 3% of total HCB in blood, intestinal excretion of unchanged HCB may account
for about 6%, thus showing the importnce of metabolism in the overall elimfination of HCB.
The elimination of HCB and metabolites by both routes, however, appears to be very small
(< 0.05%/day) as compared to the estimated HCB adipose depots. Features ofHCB kinetics that
we present in this study, i.e., nonsatted intestinal elimination of HCB and excretion in feces
and urne of inert glutathione derivatives, may explain, in part, the absence of porphyria cutaea
in this human population heavily exposed to HCB. KICy work feces, hexachlorobenzene, humans,
kdnetics, urine. Environ Heath Prspet 108:595-598 (2000). (Online 24 May 20001
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Hexachlorobenzene (HCB) is a chlorinated
hydrocarbon with a high lipophilicity and a
strong tendency to accumulate in food chains
and lipid-rich tissues of animals and humans.
It is ubiquitous in soil, water, air, and biologi-
cal matrices. HCB was used as a fungicide for
seed treatment, but most countries banned its
use during the 1970s; currently, most HCB
enters the environment by way of by-products
and emissions from the chlorinated solvent
industry. It was learned that HCB induces
porphyria in humans during an outbreak of
porphyria cutanea tarda (PCT) in Turkey in
the late 1950s, when several rural populations
consumed HCB-contaminated bread (1). The
effects of this chemical were most severe in
breast-fed infants. Several decades of research
have shown that HCB, in addition to induc-
ing porphyria, has a broad range of toxic
effects in experimental animals, including
immunotoxicity, endocrine effects, and can-
cer (1). However, because few data arose
from the Turkish outbreak, there is little
information on the threshold levels and
dose-response relationship of HCB and on
HCB-related adverse effects in humans.
Grimalt et al. (2) initiated a cross-sec-
tional research project on the health effects
ofHCB in Flix, Spain (Tarragona Province),
a rural village near a chlorinated solvent fac-
tory where high airborne HCB exposure reg-
ularly occurred during the last four decades.
In the cohort studied in Flix, it was possible
to quantify the HCB internal dose and assess
the health status, including measurements of
urinary porphyrin profiles (3-5).The authors,
however, did not find an association between
HCB serum concentrations and the appear-
ance ofPCT.
The Flix project was also intended to
study HCB disposition in humans. The exis-
tence of a cohort of individuals with the high-
est HCB serum concentrations ever reported
provided a unique opportunity to study HCB
metabolism and elimination in humans. In a
previous report (6) addressing the urinary
elimination of HCB metabolites, we found a
very strong correlation between HCB serum
concentrations and pentachlorobenzenetiol
(PCBT) in urine. PCBT is a metabolite that
arises from the conjugation ofHCB with glu-
tathione and the formation of an N-acetyl-L-
cysteine derivative (6). This metabolite was
found to be more concentrated in the urine
than pentachlorophenol (PCP), a metabolite
that arises from P450-mediated hydroxilation;
this suggests the existence of an important
detoxication pathway that leads to the forma-
tion of a mercapturic acid derivative.
A more comprehensive approach to HCB
elimination kinetics in humans, however,
required the quantification of HCB and its
metabolites in feces and the comparison
between both major elimination pathways. In
this report we present this quantification
based on a new subset of individuals from the
Flix project who provided serum, urine, and
feces samples for study.
Materials and Methods
Study population. An epidemiologic cross-
sectional study was carried out on the 4,178
inhabitants of Flix who were > 14 years of
age. A questionnaire about residence, occupa-
tion, lifestyle, and medical history was com-
pleted by 1,800 inhabitants (43% of the total
population). From these, we selected 777
individuals at random and asked them to
donate biological samples for the study. A
subset of 328 individuals responded positive-
ly. Other subjects (280) who responded to the
questionnaire but had not been selected asked
to be included. Thus, 608 individuals (328
randomly selected and 280 volunteers) pro-
vided biological samples.
Serum samples from all of these partici-
pants were analyzed to determine the HCB
concentrations. Because HCB serum concen-
trations and sociodemographic characteristics
did not differ by type of selection (3), we
grouped all of the participants (randomly
selected and volunteers).
We randomly selected a subset of 45
individuals for the present study. This result-
ed in a 10% overlapping by chance with the
former urine study (6). In addition, 8 sub-
jects with the highest blood HCB levels were
included. Thus, the final subset was 53 indi-
viduals (25 men and 28 women; mean age of
47 and 42 years, respectively). These subjects
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were informed of the purpose of the study
and provided 24-hr urine samples and feces
samples for analysis ofHCB and metabolites.
Analysis ofHCB and metabolites. Feces
and urine samples were analyzed at the
Toxicology Unit (Hospital Clinic, University
of Barcelona). Preanalytical management of
samples (identification, chain of custody,
storage, randomization of analysis order,
blinding of technicians) was accomplished
according to good laboratory practices and
approved protocols of the hospital laboratory.
Feces samples (approximately 250 mg)
were homogenized and dried at 650C
overnight. The drying process reduced the
initial weight of the samples depending on
the degree of hydration. The ratio of
dried/fresh weight x 100 ranged from 14.2%
to 55.65% [28.0 ± 9.02, arithmetic mean
(AM) ± SD]. Dried samples were weighed
and digested under N2 with 4 mL 2N
NaOH for 4 hr at 70°C . Ascorbic acid and
aldrin (as an internal standard) were added to
the mix. This alkaline hydrolysis yields free
PCP and PCBT. After cooling and acidifica-
tion with concentrated HCI (pH 1), HCB
and metabolites were extracted twice with 5
mL benzene; the solvent extracts were con-
centrated to 0.5 mL and treated with 0.5 mL
diazoethane in diethyl ether.
After derivatization (30 min in the dark),
the excess diazoethane was removed under an
N2 stream, the solvent extracts were concen-
trated to approximately 0.1 mL, and n-hexa-
ne (2 mL) was added. The resulting mixture
was cleaned with H2S04, and the organic
phase was separated and concentrated to 25
pL. HCB and ethyl derivatives of PCP and
PCBT were analyzed by gas chromatography
(GC; Hewlett Packard 5890 II, Hewlett
Packard, Palo Alto, CA) with 63Ni electron
capture detection (ECD). Recovery of HCB,
PCP, and PCBT was assayed with spiked wet
feces and ranged between 88 and 109%. The
limit of detection for HCB, PCP, and PCBT
was 5 ng/g of dry feces. Metabolites of HCB
in urine were analyzed as previously described
(6). Briefly, aliquots of 24-hr urine were
spiked with aldrin as an internal standard,
hydrolyzed with NaOH, extracted with
toluene, and derivatized with diazoethane.
The main urinary HCB metabolites (conju-
gated PCP and pentachlorophenyl N-acetyl
cysteine) were analyzed by GC-ECD as ethyl
derivatives of free PCP and PCBT and con-
firmed by selective ion monitoring mass
spectrometry (SIM-MS). Quantitation was
calculated as micrograms of metabolites
excreted in 24 hr. The detection limit was
0.5 pg/24 hr. The HCB in sera was analyzed
as previously described (6). Briefly, serum
aliquots were spiked with tetrabromoben-
zene as an internal standard and treated with
n-hexane and sulfuric acid. HCB and other
organochlorine compounds were analyzed
by GC-ECD and confirmed by mass spec-
trometry. Quantitation was calculated as
nanograms ofHCB per milliliter of serum.
Statistical analysis. Because HCB con-
centrations in feces and blood were skewed
to the right, we used the natural logarithmic
transformation (In) in the analysis.
We performed multiple linear regression
models using SSPS.PC (SPSS Inc., Chicago,
IL) to assess the association between HCB
concentrations in blood and feces (and
between blood HCB and PCBT/PCP in feces
and urine) while adjusting for other possibly
confounding variables such as sex, age, body
mass index, and current smoking status.
Results
All feces samples analyzed contained
unchanged HCB, with values ranging from
11 to 3,025 ng/g (calculated on a dry weight
basis). The AM, SD, geometric mean (GM),
and range of values are shown in Table 1,
and the frequency distribution is shown
in Figure 1.
The HCB concentration in feces was
strongly associated with HCB in serum (r =
0.85; p < 0.0001; Figure 2, Table 2), suggest-
ing that only a small amount of the chemical
found in feces is nonabsorbed intestinal
HCB. Among the remaining variables, only
sex was associated with HCB concentrations
in feces (Table 2). Because men had signifi-
cantly higher blood HCB concentrations
than women, this association between sex
and HCB in feces disappeared after adjusting
for blood HCB concentrations in a multiple
regression analysis. The association between
HCB in blood and feces was stronger in
males (slope = 0.89; SE = 0.05) than in
females (0.32; SE = 0.29), and this difference
was statistically significant (p = 0.046). The
association between HCB concentrations in
blood and those in feces was not confounded
Table 1. Concentration of HCB and its metabolites in serum, feces, and urine (n = 53).
Percent
detected AM SD GM Minimum Maximum
HCB serum (ng/mL) 100 124.2 278.2 30.2 2.4 1485.0
HCB feces (ng/g) 100 395.4 629.9 149.1 11.0 3025.0
PCP feces (ng/g) 51 12.3 16.8 6.0 5.0 70.0
PCBT feces (ng/g) 55 32.2 42.0 7.6 5.0 139.0
PCP urine (pg 24 hr) 100 3.8 4.0 2.5 0.6 18.0
PCBT urine (pg 24 hr) 100 8.8 17.0 2.6 0.5 86.9
by the variables included in Table 2. Also,
there were no differences in the association of
HCB concentrations in blood and feces by
age or body mass index.
PCP was detectable in only 51% of the
feces samples (range 5-70 ng/g; Table 1) and
PCBT was detectable in 54% (range 5-139
ng/g). We were unable to detect other
known metabolites of HCB in rodents, such
as tetrachlorohydroquinone and tetrachloro-
1,4-benzenedithiol.
As expected from the lipophilicity of the
compound, HCB could not be detected in
any of the urine samples (detection limit 0.5
ng/mL), whereas PCP and PCBT were
detected in 100% (Table 1). PCBT in urine
strongly correlated with HCB in serum (r =
0.80), thus confirming the findings of the
previous study using a different subset of
individuals (6).
The concentration of HCB in feces does
not allow a precise calculation of the amount
of HCB that is eliminated daily by the
intestines. This would require a (difficult)
collection of 24-hr feces from all of the par-
ticipants. Thus, an accurate comparison
between the amount of HCB eliminated
through feces and urine is not possible. Based
on the data in Table 1, however, we estimat-
ed the excretion of HCB in feces; these esti-
mations are presented in Table 3. Supposing
a standard volume of 5.4 L of blood in a
healthy individual who weighs 70 kg,
13-8,019 pg HCB (GM 163 jig) may be in
circulation. The 24-hr urinary output in the
form of metabolites (PCP and PCBT) ranges
30 ~
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Figure 1. Frequency distribution of HCB concen-
tration in feces.
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Figure 2. Correlation plot of HCB concentration in
feces versus HCB concentration in serum.
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between 0.9 and 105 pg (GM 5.1 pg), which
represents 3.1% of the calculated GM in cir-
culation. Calculation of the total amount of
HCB excreted in feces is far more tentative.
Assuming the standard 24-hr production of
feces to be 150-250 g (2), we used the maxi-
mum value of 250 g and an average weight
reduction of 28% after the drying process
(see "Materials and Methods") to calculate
the amount of dry feces per day: 250 g x
28% = 70 g dry feces/day. According to the
concentrations presented in Table 1, the total
daily unchanged HCB eliminated by feces
would range between 0.8 and 211.7 pg (GM
10.4 pg; 6.4% of total HCB in circulation;
Table 3). Approximately 0.9 pg 24-hr
metabolites (sum of the GM of the PCP con-
centration in feces x 70 g/24 hr dry feces =
0.42 pg plus the GM of the PCBT concen-
tration x 70 g = 0.53 pg; Table 1) could also
be excreted in feces (still only detected in
50% of the samples).
Discussion
This is the first study of humans in which
the HCB elimination pattern can be studied
in a general population highly exposed to
HCB and with the highest HCB serum con-
centrations ever reported (5). The quantita-
tive results shown in Table 1 clearly suggest
that in humans there is a major elimination
of unmetabolized HCB in feces. These find-
ings agree with studies performed in rhesus
monkeys fed [14C]HCB, which found that a
significant amount of the radioactivity detect-
ed in feces corresponded to the unchanged
parent compound (8). In mammals, the
Table 2. Levels of HCB in feces according to
selected variables.
HCB in feces (ng/g)
No. Mean (SD) GM
Sex
Women
Men
Age
<45
45-64
>64
Body mass index (kg/mr2)
<22
22-25
25-27
>27
Current smoking
No
Yes
Sample
Random
Volunteers
HCB in blood (ng/mL)
<10
10-16
16-25
>25
28 117 (79)
25 708 1813)
19 401 (547)
24 517 (778)
10 92 (56)
13 361 (594)
8 319(473)
20 347 (504)
1 1 587 (963)
37 313(481)
13 711 (932)
17 397(491)
36 394 (692)
9 57 )44)
12 83 (38)
12 125 (79)
20 .897 (808)
96
245*
138
211
75
117
112
172
194
144
233
181
130
37
76
101
523*
elimination patterns of other organochlo-
rines, such as polychlorinated biphenyls
(PCBs), polychlorinated dibenzo-p-dioxins,
and polychlorinated dibenzofurans, usually
show a shift from urine to feces. This shift
seems to be based on the size and number of
halogen substitutions in the compound; thus,
the most lipophylic congeners within each
family are eliminated primarily by feces (9).
In some cases, virtually unmetabolizable
PCB congeners (2,4,5,2',4',5'-hexachloro-
biphenyl) are eliminated only in feces (10).
According to our results for HCB, there is
not such a clear shift in humans. We found a
large amount of unchanged HCB excreted
in feces, but the polar derivatives PCP and
PCBT still make up a relatively high propor-
tion of the total output.
HCB found in feces may be, in part, the
nonabsorbed and recently ingested com-
pound. However, the strong correlation
between HCB content in feces and sera
(Figure 2) suggests an equilibrium kinetics
with very few variations because of nonab-
sorbed foodborne HCB. Previous reports
have shown that the population under study
is exposed to HCB primarily through inhala-
tion of contaminated air (2); the appearance
of a correlation between feces and blood is
compatible with a main pulmonary entrance
and incompatible with irregular amounts of
HCB that were recently ingested, not
absorbed, and currently circulate in the gas-
trointestinal tract.
Some authors have suggested that fecal
elimination of some lipophylic chemicals is
produced mainly by direct passive transfer to
the intestinal lumen and not by biliary secre-
tion (11). This could be the case for HCB in
humans because mineral oil has been shown
to stimulate the intestinal excretion of HCB
in rhesus monkeys (12). Our results do not
directly confirm this possibility, but the rela-
tively high concentrations of unchanged
HCB found in feces and the strong correla-
tion of serum and feces (which in turn sug-
gests a correlation between adipose tissue,
serum, and feces) seem compatible with the
hypothesis of a nonbiliary passive transfer
that is probably mediated by the lymphatics
independent of the liver.
The higher concentration of HCB in
feces from men as compared to women is
dependent on the higher serum HCB found
in men in this population subset. A similar
difference has also been found in the overall
serum study (5). The most probable expla-
nation for these sex differences is that more
men that women were employed in an elec-
trochemical factory, which was the main
determinant of the variation in HCB body
burden (5). The small numbers used in this
study and the wide range ofHCB body bur-
dens do not allow us to confirm possible sex-
and/or age-related variations regarding HCB
metabolism and excretion, which would
require a further investigation with a larger
number of participants.
The amount ofHCB that accumulated in
adipose tissue in this population can be esti-
mated based on the HCB adipose:serum con-
centration ratio of 246:1 (lipid weight vs.
whole weight) reported by Needham et al
(13). According to this, the population under
study may have HCB concentrations in adi-
pose tissue ranging from 0.59 to 365 pg/g
(calculated on lipid basis; AM 30 pg/g; GM
7.4 pg/g). Thus, a standard individual who
weighs 70 kg and who has 10 kg of adipose
tissue (14) could accumulate an adipose HCB
burden ranging from 5.9 to 3,653 mg (AM
300 mg; GM 74 mg). This should be correct-
ed for the percentage of extractable lipids
(approximately 75%) (15) yielding a range of
4.4-2,737 mg (AM 225 mg; GM 55.5 mg).
Calculations using the previous assump-
tions on excretion of HCB and metabolites
in feces and urine yields a total amount of
16.3 pg excreted in 24 hr (GM 10.3 pg
unchanged HCB, 5.1 pg metabolites in
urine, and 0.9 pg metabolites in feces; Table
3). These tentative calculations show that the
total daily elimination of HCB and metabo-
lites by both routes (urine and feces) may be
very small as compared to the adipose depots
(0.029%/day; relative to previously estimated
GM 55.5 mg of HCB adipose burden) and
even as compared to the total HCB in blood
(10%/day, relative to GM 163 pg; Table 3).
Assuming a first order kinetics, this excretion
rate would suppose an average estimated
whole-body HCB half-life of 6 years, which
is in accordance with the upper limit of cal-
culations made in monkeys (16).
Previous studies have addressed the
health status of this HCB-exposed human
population (2,3). An increase in soft-tissue
sarcoma and thyroid cancer in men was
observed, but prevalence of self-reported
common chronic diseases, thyroid pathology,
Table 3. Estimations of excretion of HCB in feces and metabolites in urine in relation to HCB in circulation.
Range
GM
AM
HCB in blood
(pg/5.4 L)
13-8,019
163
669
Urinary excretion
(pg PCP + PCBT/24 hr)
0.92-105
5.1 (3.1%)b
12.5 (1 .8%)c
Fecal excretion
(pg HCB/24 hr)8
0.8-211.7
10.4 (6.4%)b
27.6 (4%)c
&Estimation based on the assumption of an average excretion of 70 g dried feces/24 hr. bRelative to the calculated geo-
metric mean of HCB in blood. cRelative to the calculated arithmetic mean of HCB in blood.
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Parkinson's disease, all cancers, and repro-
ductive outcomes did not differ from other
populations. Most striking was the absence
of porphyria cutanea, a disease known to be
associated with HCB exposure in humans
(4). However, several peculiarities of HCB
kinetics that emerge from this study (adipose
sequestration, nonsaturated elimination of
unchanged compound by feces, nonsaturat-
ed formation of inert glutathione derivatives)
could explain why HCB, even present in this
human population with the highest blood
concentrations ever reported, may not be
high enough to trigger hepatic toxicity or
other effects typically associated with
organochlorines.
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